- Home
- Latest
- By speciality
- Policy
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- EACR 21
- MBCC 12
- EHA 2010
- ASCO 2010
- ELCC 2010
- AACR 2010
- EMCCC 2010
- EBCC 7
- DKK 2010
- ASH 2009
- SABCS 2009
- AORTIC
- NCRI
- ECCO 15 - ESMO 34
- 11th Milan Breast Cancer Conference 2009
- IMPAKT
- ASCO 2009
- AACR 2009
- SABCS 2008
- ASH 50th annual meeting 2008
- ESMO 33
- 10th Milan Breast Cancer Conference 2008
- EBCC 6 2008
- ECCO 14 2007
- By continent
- Latest technologies
- Education
- Most viewed
- View all
Expert Interview Chris Twelves
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Professor Chris Twelves - St James's Hospital, Leeds, UK
New agent eribulin prolongs survival in metastatic breast cancer
A new study presented at ASCO has found that eribulin can extend the survival rates of women with locally recurrent or metastatic breast cancer in women who have already received extensive standard therapy. Prof Twelves who helped designed the trial talks to Prof McVie about the findings.
Supported by an educational grant from Eisai Pharma Europe Ltd.
Click here to watch Prof Christopher Twelves' press briefing from ASCO 2010
Expert interview with Chris Twelves
Target audience:
This educational activity is intended for medical, surgical and radiation oncologists, as well as allied oncology professionals who treat breast cancer.
Statement of need:
While early detection by breast cancer screening and the development of innovative drugs have contributed to the decline in breast cancer mortality around the world, breast cancer remains one of the leading causes of cancer death in women. Women with locally advanced or metastatic breast cancer have limited treatment options and the development of more effective treatment or anti-cancer drugs is critically important. This interview will provide clinicians with an invaluable understanding of the latest drug developments for the treatment of advanced or metastatic breast cancer.
Learning objective:
After watching the video the viewer should be able to:
- Understand the latest drug developments for locally advanced or metastatic breast cancer
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This material was developed for use outside of the US and is to be used in accordance with local laws and regulations.
Supported by an educational grant from Eisai Pharma Europe Ltd
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment